Grail

Grail ROE

The Return on Equity (ROE) of Grail (GRAL) as of Oct 15, 2026 is -15.84 %. In the previous year, Return on Equity (ROE) was -80.97 % — a change of -80.44% (higher).

ROE

-15.84 %

YoY

-80.44%

Last updated:

In 2025, Grail's return on equity (ROE) was -15.84 %, a -80.44% increase from the -80.97 % ROE in the previous year.

The Grail ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-45.92 USD
Jan 1, 2019
-44.48 USD
Jan 1, 2020
-55.56 USD
Jan 1, 2021
-13.23 USD
Jan 1, 2022
-116.21 USD
Jan 1, 2023
-40.20 USD
Jan 1, 2024
-80.97 USD
Jan 1, 2025
-15.84 USD
The Grail ROE history
YEARROEYoY
-15.84 %-80.44%
-80.97 %+101.43%
-40.20 %-65.41%
-116.21 %+778.27%
-13.23 %-76.19%
-55.56 %+24.92%
-44.48 %-3.15%
-45.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grail Stock analysis

What does Grail do? Grail Inc, with ticker GRAL and ISIN US3847471014, is a US-based biotechnology company headquartered in Menlo Park. The company operates within the Health Care sector and has 910 employees. Grail Inc. went public on June 12, 2024. The company's website is https://www.galleri.com/. Grail Inc. focuses on early cancer detection through advanced technologies including next-generation sequencing, population-scale clinical studies, and machine learning. Its platform utilizes methylation-based approaches to support cancer screening and precision oncology, targeting multiple cancer types for early detection. The company's products include Galleri, a screening test for multi-cancer early detection, which helps guide healthcare decisions for cancer diagnosis. Grail Inc. aims to shift paradigms in cancer detection by identifying diseases at earlier stages, thereby alleviating the global burden of cancer. The company's approach integrates software, automation, and data analysis to enhance the continuum of care for cancer patients. Grail Inc. is engaged in developing solutions for cancer screening, risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring, and recurrence tracking. The company's work is centered on improving outcomes through early intervention and personalized treatment strategies. The focus on early detection aligns with efforts to reduce cancer mortality rates and improve patient survival rates globally. Grail Inc. operates with a technology-driven approach to revolutionize cancer care through innovative diagnostic tools and methodologies. Grail is one of the most popular companies on Eulerpool.

ROE Details

Decoding Grail's Return on Equity (ROE)

Grail's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Grail's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Grail's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Grail’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Grail stock

Return on Equity (ROE) of Grail is -15.84 % in 2025.

Return on Equity (ROE) of Grail changed from -80.97 % to -15.84 %, representing a -80.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Grail since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Grail with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Grail

All Key Metrics — Grail